Compare FTLF & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | SAVA |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.8M | 157.0M |
| IPO Year | N/A | N/A |
| Metric | FTLF | SAVA |
|---|---|---|
| Price | $17.68 | $2.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.00 | $5.00 |
| AVG Volume (30 Days) | 13.4K | ★ 1.1M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $70,561,000.00 | N/A |
| Revenue This Year | $34.34 | N/A |
| Revenue Next Year | $48.58 | N/A |
| P/E Ratio | $25.78 | ★ N/A |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $9.83 | $1.15 |
| 52 Week High | $20.98 | $4.98 |
| Indicator | FTLF | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 44.47 |
| Support Level | $17.62 | $2.95 |
| Resistance Level | $19.23 | $3.45 |
| Average True Range (ATR) | 0.87 | 0.24 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 11.22 | 33.73 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.